source
- Beam Therapeutics' base-edited sickle cell therapy shows success in Phase 1/2 trialBeam Therapeutics announced on Tuesday that its base-edited gene therapy for sickle cell disease met its primary endpoints in a Phase 1/2 study. The trial demonstrated that a single administration…
- PepGen reports positive Phase 2 data for PGN-EDODM1 in myotonic dystrophyPepGen disclosed that its experimental oligonucleotide therapy PGN-EDODM1 showed encouraging early signals in a Phase 2 cohort of patients with myotonic dystrophy type 1 (DM1). The company said the…